NASDAQ : SLBT
SL Science Holding Limited — Financial statements
Healthcare · Biotechnology · Taiwan
Last price 1.17 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 667.21M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
SL Science Holding Limited (SLBT) reported revenue of 3.27M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue | 3.27M | 3.36M | 878.97K |
| Cost of Revenue | 2.01M | 1.43M | 140.96K |
| Gross Profit | 1.26M | 1.93M | 738.01K |
| Selling, General & Admin | 1.78M | 1.11M | 641.18K |
| Research & Development | 1.78M | 2.02M | |
| Operating Expenses | 3.57M | 3.13M | 641.18K |
| Operating Income | -2.31M | -1.20M | 96.83K |
| Interest & Investment Income | 71.46K | 45.30K | 1.61K |
| Other Non Operating Income (Expenses) | -25.44K | 17.11K | 434.43K |
| Pretax Income | -2.26M | -1.13M | 532.87K |
| Income Tax Expense | 105.17K | 57.63K | 133.84K |
| Net Income | -2.37M | -1.19M | 399.04K |
| Net Income to Common | -2.37M | -1.19M | 399.04K |
| Shares Outstanding (Basic) | 3.67M | 2.63M | |
| Shares Outstanding (Diluted) | 3.67M | 2.63M | |
| EPS (Basic) | -0.64 | -0.45 | |
| EPS (Diluted) | -0.64 | -0.45 | |
| Free Cash Flow | -3.28M | 272.19K | -2.64M |
| Free Cash Flow Per Share | -0.89 | 0.10 | |
| Gross Margin | 38.41% | 57.46% | 83.96% |
| Operating Margin | -70.65% | -35.56% | 11.02% |
| Profit Margin | -72.46% | -35.42% | 45.40% |
| Free Cash Flow Margin | -100.30% | 8.09% | -300.04% |
| EBITDA | -2.28M | -1.15M | 129.95K |
| EBITDA Margin | -69.87% | -34.27% | 14.79% |
| D&A For EBITDA | 25.47K | 43.31K | 33.12K |
| EBIT | -2.31M | -1.20M | 96.83K |
| EBIT Margin | -70.65% | -35.56% | 11.02% |
| Effective Tax Rate | 25.12% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2024 | FY2023 | |
|---|---|---|---|
| Cash & Equivalents | 3.37M | 3.68M | 276.85K |
| Cash & Short-Term Investments | 3.37M | 3.68M | 276.85K |
| Accounts Receivable | 26.88K | ||
| Other Receivables | 119.71K | 265.28K | 91.40K |
| Receivables | 119.71K | 265.28K | 118.28K |
| Inventory | 722.75K | 1.36M | 2.94M |
| Prepaid Expenses | 44.07K | 64.11K | 423.00 |
| Restricted Cash | 172.00K | 457.50K | 162.50K |
| Other Current Assets | 28.35K | 28.49K | 163.00 |
| Total Current Assets | 4.46M | 5.86M | 3.49M |
| Property, Plant & Equipment | 667.02K | 18.98K | 740.95K |
| Other Intangible Assets | 7.52K | ||
| Long-Term Deferred Charges | 664.37K | 50.00K | |
| Other Long-Term Assets | 7.80K | ||
| Total Assets | 5.79M | 5.93M | 4.24M |
| Accrued Expenses | 704.16K | 59.07K | 28.89K |
| Current Portion of Leases | 154.92K | 149.59K | |
| Other Current Liabilities | 51.27K | 10.13K | 4.55K |
| Total Current Liabilities | 910.36K | 69.20K | 183.03K |
| Long-Term Leases | 150.75K | 400.48K | |
| Long-Term Deferred Tax Liabilities | 135.70K | 84.56K | |
| Total Liabilities | 1.06M | 204.90K | 668.07K |
| Common Stock | 367.50K | 367.50K | 150.00K |
| Additional Paid-In Capital | 6.93M | 6.80M | |
| Retained Earnings | -3.27M | -1.66M | |
| Comprehensive Income & Other | 698.28K | 228.47K | 3.42M |
| Shareholders' Equity | 4.73M | 5.73M | 3.57M |
| Total Liabilities & Equity | 5.79M | 5.93M | 4.24M |
| Total Debt | 305.67K | 550.06K | |
| Net Cash (Debt) | 3.07M | 3.68M | -273.21K |
| Net Cash Per Share | 0.83 | 1.40 | |
| Filing Date Shares Outstanding | 3.67M | 3.67M | |
| Total Common Shares Outstanding | 3.67M | 3.67M | |
| Working Capital | 3.55M | 5.79M | 3.31M |
| Book Value Per Share | 1.29 | 1.56 | |
| Tangible Book Value | 4.73M | 5.73M | 3.57M |
| Tangible Book Value Per Share | 1.29 | 1.56 | |
| Machinery | 49.12K | 28.47K | 225.56K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2024 | FY2023 | |
|---|---|---|---|
| Net Income | -2.37M | -1.19M | 399.04K |
| Depreciation & Amortization | 25.47K | 43.31K | 33.12K |
| Other Amortization | 3.94K | 3.94K | 4.07K |
| Loss (Gain) From Sale of Assets | -6.25K | -6.25K | |
| Other Operating Activities | 157.61K | 165.42K | 173.17K |
| Change in Accounts Receivable | 57.00K | 25.83K | -26.63K |
| Change in Inventory | 1.99M | 1.59M | -2.94M |
| Change in Other Net Operating Assets | -2.91M | -405.51K | -235.00K |
| Operating Cash Flow | -2.95M | 280.16K | -2.45M |
| Capital Expenditures | -325.65K | -7.97K | -182.98K |
| Sale of Property, Plant & Equipment | 127.81K | 127.81K | |
| Sale (Purchase) of Intangibles | 3.45K | 3.45K | |
| Investing Cash Flow | -194.39K | 123.28K | -182.98K |
| Issuance of Common Stock | 7.24M | 2.86M | |
| Other Financing Activities | -664.37K | -4.17M | |
| Financing Cash Flow | -664.37K | 3.07M | 2.86M |
| Foreign Exchange Rate Adjustments | 486.95K | 228.66K | -7.16K |
| Net Cash Flow | -3.33M | 3.70M | 216.49K |
| Free Cash Flow | -3.28M | 272.19K | -2.64M |
| Free Cash Flow Margin | -100.30% | 8.09% | -300.04% |
| Free Cash Flow Per Share | -0.89 | 0.10 | |
| Levered Free Cash Flow | 372.34K | ||
| Unlevered Free Cash Flow | 372.34K | ||
| Change in Working Capital | -765.55K | 1.27M | -3.06M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2024 | FY2023 | |
|---|---|---|---|
| Debt / Equity Ratio | 0.07 | 0.15 | |
| Debt / EBITDA Ratio | 1.81 | ||
| Net Debt / Equity Ratio | -0.65 | -0.64 | 0.08 |
| Net Debt / EBITDA Ratio | 1.34 | 3.19 | 2.10 |
| Net Debt / FCF Ratio | 0.94 | -13.52 | -0.10 |
| Asset Turnover | 0.66 | ||
| Inventory Turnover | 0.67 | ||
| Quick Ratio | 3.84 | 57.02 | 2.16 |
| Current Ratio | 4.90 | 84.61 | 19.09 |
| Return on Equity (ROE) | -25.62% | ||
| Return on Assets (ROA) | -14.70% | ||
| Return on Invested Capital (ROIC) | -138.93% | -40.59% | 1.88% |
| Return on Capital Employed (ROCE) | -47.30% | -20.40% | 2.40% |